References
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI: 10.3322/caac.21834
- Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24-38. DOI: 10.1038/s41391-018-0079-0
- Shiner A, Sperandio RC, Naimi M, Emmenegger U. Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies. J Clin Med. 2024;13(3). DOI: 10.3390/jcm13030734
- Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129-36. DOI: 10.1016/j.ajur.2018.11.007
- Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):1-11. DOI: 10.1186/s12916-021-02230-y
- Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. DOI: 10.1056/NEJMoa031918
- Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst - Monogr. 2012;2011(45):146-51. DOI: 10.1093/jncimonographs/lgs031
- Dunne JC, Lamb DS, Delahunt B, Murray J, Bethwaite P, Ferguson P, et al. Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clin Proteomics. 2015;12(1). DOI: 10.1186/s12014-015-9096-3
- Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, et al. Proteomic tissue-based classifier for early prediction of prostate cancer progression. Cancers (Basel). 2020;12(5):1-21. DOI: 10.3390/cancers12051268
- Bărar AA, Pralea IE, Maslyennikov Y, Munteanu R, Berindan-Neagoe I, Pîrlog R, et al. Minimal Change Disease: Pathogenetic Insights from Glomerular Proteomics. Int J Mol Sci. 2024 May 21;25(11):5613. DOI: 10.3390/ijms25115613
- Bărar AA, Pralea IE, Berindan-Neagoe I, Pirlog R, Nutu A, Maslyennikov Y, et al. Proteomic patterns in glomerular research, a laser capture microdissection and liquid chromatography-tandem mass spectrometry approach. Rev Rom Med Lab. 2023 Oct 1;31(4):263-74. DOI: 10.2478/rrlm-2023-0029
- Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735-61. DOI: 10.1038/s41596-022-00710-w
- Xie Z, Bailey A, Kuleshov M V., Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1(3):1-84. DOI: 10.1002/cpz1.90
- Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science (80- ). 2015;347(6220). DOI: 10.1126/science.1260419
- Hernández J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894-904. DOI: 10.1002/cncr.20480
- Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006;98(19):1420-4. DOI: 10.1093/jnci/djj378
- Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol. 2017;28(8):1903-9. DOI: 10.1093/annonc/mdx247
- Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT. Cell Stress Induced Stressome Release Including. Cells. 2020;9(755). DOI: 10.3390/cells9030755
- Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):1-47. DOI: 10.3390/ijms21124507
- Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, et al. Glucose metabolism in the progression of prostate cancer. Front Physiol. 2017;8(FEB). DOI: 10.3389/fphys.2017.00097
- Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:1-13. DOI: 10.1186/1476-4598-3-29
- Pircher A, Schäfer G, Eigentler A, Pichler R, Puhr M, Steiner E, et al. Robo 4-the double-edged sword in prostate cancer: Impact on cancer cell aggressiveness and tumor vasculature. Int J Med Sci. 2019;16(1):115-24. DOI: 10.7150/ijms.28735
- Habrowska-Górczyńska DE, Kozieł MJ, Kowalska K, Piastowska-Ciesielska AW. FOXO3a and its regulators in prostate cancer. Int J Mol Sci. 2021;22(22). DOI: 10.3390/ijms222212530
- Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, et al. Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling. Eur J Cancer. 2022;174(6611):S4-5. DOI: 10.1016/S0959-8049(22)00818-8
- Hoshi S, Meguro S, Imai H, Matsuoka Y, Yoshida Y, Onagi A, et al. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci. 2021;112(5):1899-910. DOI: 10.1111/cas.14865
- Bonaterra GA, Schleper A, Skowronek M, Kilian LS, Rink T, Schwarzbach H, et al. Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia. Cancers (Basel). 2022;14(19). DOI: 10.3390/cancers14194591
- Mahon KL, Sutherland SIM, Lin HM, Stockler MR, Gurney H, Mallesara G, et al. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. Prostate. 2024;84(8):747-55. DOI: 10.1002/pros.24691
- Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells. J Immunol. 2006;177(12):8730-9. DOI: 10.4049/jimmunol.177.12.8730
- Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002 Mar 11;94(5):1449-56. DOI: 10.1002/cncr.10354
- Muramaki M, Miyake H, Yamada Y, Hara I. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep. 2006 Jan 1;253-7. DOI: 10.3892/or.15.1.253
- Tekin B, Dasari S, Theis JD, Vrana JA, Murray DL, Oglesbee D, et al. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15. Hum Pathol. 2023;135:35-44. DOI: 10.1016/j.humpath.2023.03.001
- Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory fator expression in prostate cancer. BMC Cancer. 2005;5:1-12. Available from: DOI: 10.1186/1471-2407-5-73 DOI: 10.1186/1471-2407-5-73
- Zhou B, Ren C, Zu L, Zheng L, Guo L, Gao W. Elevated plasma migration inhibitory factor in hypertension-hyperlipidemia patients correlates with impaired endothelial function. Medicine (Baltimore). 2016 Oct;95(43):e5207. DOI: 10.1097/MD.0000000000005207
- Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, et al. Association of Systemic Concentrations of Macrophage Migration Inhibitory Factor With Impaired Glucose Tolerance and Type 2 Diabetes. Diabetes Care. 2006 Feb 1;29(2):368-71. DOI: 10.2337/diacare.29.02.06.dc05-1474
- Sarkar S, Legere S, Haidl I, Marshall J, Macleod JB, Aguiar C, et al. Serum GDF15, a promising biomarker in obese patients undergoing heart surgery. Front Cardiovasc Med. 2020;7(June). DOI: 10.3389/fcvm.2020.00103
- Bansal N, Kumar D, Gupta A, Chandra D, Sankhwar SN, Mandhani A. Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation. Sci Rep. 2017 Dec 4;7(1):16824. DOI: 10.1038/s41598-017-17207-2
- Song H, Shen Q, Hu S, Jin J. The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling. Biol Open. 2020;9(11):1-7. DOI: 10.1242/bio.053447
- Sörensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R. Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol. 2013;14(1):1-6. DOI: 10.1186/1471-2369-14-145
- Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6):1265-72. DOI: 10.1093/carcin/bgt056